Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 23, 2015MYO-DEN InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1715-2015Class IITerminatedSep 23, 2015Myers Cocktail InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1714-2015Class IITerminatedSep 23, 2015Morphine 60 mg/ml + Fentanyl 12Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1713-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 20Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1712-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Ropivacaine 5 mg/ml +Baclofen 20 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1711-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 3Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1710-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 3Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1709-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1708-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 10Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1707-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1706-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Clonidine 750 mcg/ml + Baclofen 15 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1705-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Clonidine 500 mcg/ml +Bupivacaine 2.5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1704-2015Class IITerminatedSep 23, 2015Morphine 45 mg/ml + Bupivacaine 8 mg/ml + Baclofen 25 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1703-2015Class IITerminatedSep 23, 2015Morphine 25 mg/ml + Bupivacaine 30 mg/ml + Clonidine 200 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1702-2015Class IITerminatedSep 23, 2015Morphine 25 mg/ml + Bupivacaine 20 mg/ml + Clonidine 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1701-2015Class IITerminatedSep 23, 2015MEGA-BURN* InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1700-2015Class IITerminatedSep 23, 2015MEGA-BURN III InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1699-2015Class IITerminatedSep 23, 2015MEGA-BURN IV InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1698-2015Class IITerminatedSep 23, 2015MEGA-BURN Injectable ROCK CREEKLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1697-2015Class IITerminatedSep 23, 2015MEGA-BURN InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1696-2015Class IITerminatedSep 23, 2015Lipovicine-Choline 100 mg/ml-Acorbic Acid 45 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1695-2015Class IITerminatedSep 23, 2015Lipovicine Modified II InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1694-2015Class IITerminatedSep 23, 2015Lipotropic Methyl B-12 InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1693-2015Class IITerminatedSep 23, 2015Lipotropic B-12 II* + Lidocaine InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1692-2015Class IITerminatedSep 23, 2015Lipotropic B-12 InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1691-2015Class IITerminatedSep 23, 2015LipotropicLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1690-2015Class IITerminatedSep 23, 2015LIPO-VITE IIILack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1689-2015Class IITerminatedSep 23, 2015LIPO-VITE InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1688-2015Class IITerminatedSep 23, 2015LIPO-Tropic InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1687-2015Class IITerminatedSep 23, 2015LIPO-EXTREME InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1686-2015Class IITerminatedSep 23, 2015LIPO-DEN MODIFIED InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1685-2015Class IITerminatedSep 23, 2015Lipo-DEN III InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1684-2015Class IITerminatedSep 23, 2015Lipo-B MMC ILack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1683-2015Class IITerminatedSep 23, 2015Hydromorphone 80 mg/ml + Bupivacaine 10 mg/ml + Clonidine 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1682-2015Class IITerminatedSep 23, 2015Hydromorphone 70 mg/ml +Fentanyl 16Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1681-2015Class IITerminatedSep 23, 2015Hydromorphone 70 mg/ml + Bupivacaine 20 mg/ml + Clonidine 125 mcg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1680-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Fentanyl 7Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1679-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Fentanyl 15Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1678-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Fentanyl 20Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1677-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Fentanyl 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1676-2015